Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer-Reference-Cited by-同舟云学术

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Published:2020-12-12 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Sathianathen Niranjan J¹,Oestreich Makinna C²,Brown Sarah Jane³,Gupta Shilpa⁴,Konety Badrinath R¹,Dahm Philipp⁵,Kunath Frank⁶

Affiliation:

1. Department of Urology; University of Minnesota; Minneapolis Minnesota USA

2. University of Minnesota Medical School; University of Minnesota; Minneapolis Minnesota USA

3. Health Sciences Libraries; University of Minnesota; Minneapolis Minnesota USA

4. Department of Medicine, Division of Hematology, Oncology and Transplatation; University of Minnesota; Minneapolis Minnesota USA

5. Urology Section; Minneapolis VA Health Care System; Minneapolis Minnesota USA

6. Department of Urology; University Hospital Erlangen; Erlangen Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Reference82 articles.

1. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO);CHi;Annals of Oncology,2017

2. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial;CHi;Journal of Clinical Oncology,2018

3. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial;Chi;Lancet Oncology,2018

4. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study;Feyerabend;Target Oncology,2019

5. Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial;Fizazi;Journal of Clinical Oncology,2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A case report of sustained remission after radiotherapy combined with ICI in NEPC with primary drug resistance to chemotherapy;Frontiers in Oncology;2024-04-26

2. Influence of Androgen Deprivation Therapy on the Development of Sarcopenia in Patients with Prostate Cancer: A Systematic Review;Nutrients;2024-02-26

3. Efficacy of Treatment for Metastatic Hormone-Sensitive Prostate Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses;Cancers;2023-12-06

4. Validity and Future of Primary Androgen Deprivation Therapy in Prostate Cancer. Integration in the Era of New Agents Targeting the Androgen Receptor;Archivos Españoles de Urología;2023

5. Observation of Serological Index and Efficacy of Abiraterone Hydrochloride Tablets Combined with Endocrine Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer;Archivos Españoles de Urología;2023